

Date: September 21, 2021

<p>To, The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, C – 1, Block – G, Bandra – Kurla Complex, Bandra (E), Mumbai-400 051. Scrip Code – LINCOLN</p>	<p>To, The Department of Corporate Service, BSE Limited, 1st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai – 400 001. Scrip Code – 531633</p>
--	--

Dear Sir,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Media Release on Lincoln Pharmaceuticals Ltd plans to launch Cephalosporin products soon: Acquires a plant in Mehsana, Gujarat.

With reference to the above captioned subject, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Press Release titled "Lincoln Pharmaceuticals Ltd plans to launch Cephalosporin products soon: acquires a plant in Mehsana, Gujarat."


We request you to take the same on record.

Thanking you,

Yours faithfully,

FOR LINCOLN PHARMACEUTICALS LTD

H.A. Desai



**NIREN A. DESAI
COMPANY SECRETARY &
COMPLIANCE OFFICER**

Encl: A/A



LINCOLN
PHARMACEUTICALS LIMITED
HEALTHCARE FOR ALL

Media Release

Lincoln Pharmaceuticals Ltd plans to launch Cephalosporin products soon: acquires a plant in Mehsana, Gujarat.

Acquisition funded from Internal accruals; Expects turnover of ₹ 150 crore in next 3 years


Highlights:-

- Investment in Cephalosporin plant for ₹ 30 crore including capacity expansion;
- Plant will cater to all the Cephalosporin products of tablet, capsule, dry syrup and injectables;
- Cephalosporins are used to treat infections caused by susceptible bacteria i.e. Bone Infections, Ear Infections, Skin Infections, Urinary tract Infections etc.;
- Lincoln Pharma is a Net debt-free company;
- Company is in the process of applying for WHO GMP certification for the Cephalosporin Plant;
- Company will launch Cephalosporin products in the Indian market by March 2022; Looks to export in African, Latin America and Southeast Asia markets after necessary approvals.

Ahmedabad, September 21, 2021: Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies is planning to launch Cephalosporin products soon. Company has acquired a facility in Mehsana, Gujarat. Investment in Cephalosporin plant for ₹ 30 crore including Capacity expansion and modernisation of the facility. Acquisition and further capex will be funded from internal accruals. Company expects commercial operations from March 2022. The plant is expected to contribute sales of around ₹ 150 crore in the next 3 years. The plant will cater to all the Cephalosporin products i.e. Tablet, Capsule, Dry syrup and Injectable.

The acquired facility in Mehsana, Gujarat has been designed as per the PIC's and European Region. Company is in the process of applying for WHO GMP Certifications for the facility and expects to receive the same by December 2021. Company is planning to manufacture 20 plus Cephalosporin products and is planning to start product registration soon for the domestic and exports market.

Cephalosporin is a bactericidal, broad-spectrum, and β -lactam antibiotic originally derived from fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis and others.



Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Katol, Dist. Gandhinagar, (Guj.) | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com



014



LINCOLN
PHARMACEUTICALS LIMITED

HEALTHCARE FOR ALL

Commenting on the development, **Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited**, said, "The entire expansion for Cephalosporin products will be funded from internal accruals. The Company has earmarked total investment of around ₹ 30 crore for this expansion. Company expects commercial production of the Cephalosporin products by March 2022. In the next 3 years, the facility is expected to contribute sales of around ₹ 150 crore from domestic markets as well as exports."

Company plans to manufacture 20 plus Cephalosporin products including Cefalexin Oral Suspension BP, Clavulanate Tablets, Cefixime Capsules, Cefuroxime Axetil Tablets among others. Company also looks to export in African, Latin America and Southeast Asia markets and expand to other markets after necessary approvals.

Recently, National Company Law Tribunal, Ahmedabad Bench has approved the scheme of amalgamation of Lincoln Parenteral Ltd and Lincoln Pharmaceuticals Ltd. Amalgamation is expected to bring a synergies in terms of operations efficiency, enhance competitive strength, cost-effectiveness and productivity for the combined entity.

The liquidity position of the company is on a strong foundation, supported by healthy cash accruals, and healthy return ratios. Over the last 5 years, the company has delivered a 20% plus CAGR in profits and higher single digit growth in sales. Backed by improvement in the company's financial risk profile, steady growth in scale & margins, healthy profitability, rating agency ICRA has upgraded the company's long-term and short-term bank facilities to A and A1 respectively.

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, WHO-GMP and ISO-9001:2015. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents. Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country.

-- * -- * -- * --

About Lincoln Pharmaceuticals Ltd <https://www.lincolnpharma.com/>

Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others.

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, [Guj.] | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com



The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with a vision for nurturing innovations and bringing them to Indian patients at an affordable cost to create "Healthcare for All".

Lincoln Pharma has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by WHO-GMP and ISO-9001: 2015. Recently company has also received European Union (EU) GMP certification for its manufacturing facility which will allow it to market its products in all the 27 member countries of EU and also give access to European Economic Area (EEA) countries. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D centre of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Company has a strong presence in the domestic market nationally with a dedicated field force of over 600 personnel who cater to more than 30,000 doctors, chemists across the country. Company has a wide national distribution network through 21+ Super Stockist and over 50,000 retailers in 26 states across India.

Going green, company has also set up a new Solar Plant of 1 MW at factory's rooftop in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

For further information please contact:

Gopal Modi / Rupesh Panchal
ColdCoco Consultancy, Ahmedabad
9099030184 / 9925023103
gopal@coldcococonsultancy.com
rupesh@coldcococonsultancy.com

Darshit A. Shah (CFO)
Lincoln Pharmaceuticals Limited, Ahmedabad
+91-79-4107-8048
darshit@lincolnpharma.com

